Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Inhibits Proximal TCR Signaling by Targeting ZAP-70

Zhangguo Chen, Lanfen Chen, Shuo-Wang Qiao, Takashi Nagaishi and Richard S. Blumberg

*J Immunol* 2008; 180:6085-6093; doi: 10.4049/jimmunol.180.9.6085

http://www.jimmunol.org/content/180/9/6085

---

**References** This article cites 52 articles, 22 of which you can access for free at: [http://www.jimmunol.org/content/180/9/6085.full#ref-list-1](http://www.jimmunol.org/content/180/9/6085.full#ref-list-1)

**Subscription** Information about subscribing to *The Journal of Immunology* is online at: [http://jimmunol.org/subscription](http://jimmunol.org/subscription)

**Permissions** Submit copyright permission requests at: [http://www.aai.org/About/Publications/JI/copyright.html](http://www.aai.org/About/Publications/JI/copyright.html)

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: [http://jimmunol.org/alerts](http://jimmunol.org/alerts)
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Inhibits Proximal TCR Signaling by Targeting ZAP-70

Zhangguo Chen, Lanfen Chen, Shuo-Wang Qiao, Takashi Nagaishi, and Richard S. Blumberg

The long cytoplasmic tail (CT) isoforms of carcinoembryonic Ag-related cell adhesion molecule 1 (CEACAM1) are expressed on activated human T cells and possess two ITIM motifs in the CT. These isoforms of CEACAM1 are inhibitory for T cell responses initiated by the TCR/CD3 complex with the inhibition dependent upon the ITIMs of CEACAM1 and Src homology 2 domain-containing phosphatase 1 (SHP-1). However, the mechanism by which this inhibition occurs in T cells is unknown. We demonstrate here that the Src family kinase, Lck, and the ability of CEACAM1 to bind homophilically are required for the ITIM phosphorylation of CEACAM1 that is a prerequisite for CEACAM1 association with SHP-1. We further show that CEACAM1 associates with and recruits SHP-1 to the TCR/CD3 complex leading to decreased phosphorylation of CD3-ζ and ZAP-70 and consequently decreased activation of the elements downstream of ZAP-70. This is physiologically relevant because extinction of SHP-1 expression or blockade of homophilic binding by CEACAM1 using a Fab that specifically recognizes the homophilic binding region of human CEACAM1 increases the cytoplasmic function initiated by the TCR/CD3 complex. These studies show that long CT isoforms of CEACAM1 orchestrate an inhibitory program that abrogates extremely proximal events downstream of the TCR/CD3 complex by focusing on the activation of ZAP-70.


T he T cell activation and T cell-mediated immune responses are regulated by coordinate signaling emanating from the TCR/CD3 complex and coactivating and coinhibitory receptors (1, 2). The most well studied examples of such coreceptors are the CD28/CTLA-4 family members (3, 4). Additional regulatory molecules that function as T cell coactivating or coinhibitory receptors have been described (2). We and others have recently defined carcinoembryonic Ag (CEA)3 related cell adhesion molecule 1 (CEACAM1) as a T cell inhibitory receptor which down-regulates TCR/CD3 signaling and T cell-mediated inflammation (5–10).

CEACAM1, also known as CD66a or biliary glycoprotein, belongs to the CEA family of Ig-like receptors (11, 12). CEACAM1 is expressed in polarized epithelia, blood vessel endothelia, granulocytes, macrophages, B cells, NK cells, and platelets. CEACAM1 expression is induced on the surface of all activated human and mouse T cells when examined ex vivo with limited cell surface expression in the absence of activation (13–15). CEACAM1 proteins consist of a membrane distal N-domain, variable numbers of extracellular Ig-like domains, a common transmembrane domain, and either a 10 amino acid short (S) cytoplasmic tail (CT) or a 72 amino acid long (L) CT. The N-domain contains a motif that mediates homophilic interactions with CEACAM1 either homotypically between the same types of cells or heterotypically between different types of cells as well as heterophilic interactions with other CEACAM family members and a certain group of pathogens. Through these interactions, CEACAM1 has been shown to regulate a variety of cellular functions that include angiogenesis, epithelial cell differentiation and polarization, and hematopoietic cell activity (12, 14, 16–21).

CEACAM1 L CT isoforms have shown the general property of inhibiting a variety of cell types, that include intestinal epithelial cells, B cells, NK cells, and T cells (10, 22–24). Deletion of CEACAM1 or overexpression of CEACAM1 L CT isoforms specifically within T cells results in increased and decreased TCR signaling (7), respectively. Moreover, when examined in each of these cell types, this inhibition generally involves the ITIM domains in the CT and Src homology 2 domain phosphatase 1 (SHP-1) (5, 7, 8). However, the mechanism by which the interactions between the ITIM domains of CEACAM1 L isoforms and SHP-1 mediate inhibition is unexplained, and the molecular elements that precede and follow these interactions are not defined in T cells. In this study, we demonstrate that in T cells, ITIM phosphorylation of CEACAM1 and, consequently, association with SHP-1 requires p56 Lck kinase and the ability tobind homophilically. Moreover, we show that CEACAM1 associates with and recruits SHP-1 to the TCR signalsome where SHP-1 blocks ZAP-70 activation via dephosphorylation of CD3-ζ and/or ZAP-70. This is confirmed to be physiologically relevant because masking of the homophilic binding site of CEACAM1 with Fab that specifically interact with the homophilic binding motif leads to increased cytotoxicity and lymphocyte degranulation.

Materials and Methods

Cells and cell culture

Human peripheral blood T cells were isolated from leukopacks (Brigham and Women’s Hospital Blood Center) using a human (h) pan-T cell isolation kit (Miltenyi Biotec). Cells were cultured with RPMI 1640...
supplemented with 100 U/ml rh-IL-2 (BD Pharmingen) and 2 µg/ml PHA. Clonally expanded hCD8+ and hCD4+ T cell lines were kindly provided by Dr. Bana Jabri (University of Chicago, Chicago, IL) and cultured as described previously (25). Jurkat T cells stably transduced with hCEACAM1–4L, hCEACAM1–4S were kindly provided by Dr. John Shively (Beckman Research Institute of the City of Hope, Duarte, CA). Human leukemia CD8+ T cell line TALL 104 (TALL) and J.cami.6 T cells were purchased from American Type Culture Collection.

Abs and reagents

The mouse anti-hCEACAM1 mAbs 5F4 and 34B1 (IgG1) were generated as previously described (26). Biotinylated 5F4 was made with EZ-Link sulfo-NHS-Biotin reagent according to instruction of the manufacturer Pierce. 5F4 Fab were prepared as per the manufacturer’s instructions (Pierce). Mouse anti-hCD3, isotype control IgG, PE-conjugated mouse anti-HLamp1 (CD107a), and rh-IL-2 were purchased from BD Pharmingen. Anti-phosphotyrosine mAb 4G10 and active ZAP-70 recombiant protein were purchased from Upstate Biotechnology. F(ab′)2 goat anti-mouse was obtained from Jackson Immunoresearch Laboratories. Mouse anti-ERK, phospho(p)-ERK, anti-hCD3-ζ, p-CD3-ζ, anti-TCR-β, and rabbit anti-TCR-α were from Santa Cruz Biotechnology. Rabbit anti-ZAP70, p-ZAP70, p-linker for activation of T cells (LAT), and SLP-76 were from Cell Signaling Technology. Rabbit anti-SHP-1 mAb was from Epitomics, p-ZAP70, p-linker for activation of T cells (LAT), and SLP-76 were from Cell Signaling Technology. Rabbit anti-SHP-1 mAb was from Epitomics, and anti-p-p56 Lck was from Calbiochem.

Plasmids, short interfering RNA (siRNA), and transfection

The hCEACAM1–3L and -3S, as well as CEACAM1–3L–FF mutant constructs, were previously generated (5). Jurkat and Lck-deficient Jurkat (J.cam.1.6) T cells were transfected with nucleofector kit V from Amaxa according to the manufacturer’s instructions. Homophilic binding deficient hCEACAM1–3L was generated by replacing 43 arginine (R) with glycine (G) and 44 glutamine (Q) with leucine (L) (R43G Q44L) using a site-directed mutagenesis kit from Stratagene. N-terminal Flag tagged wild-type (WT) and R43G Q44L mutant CEACAM1–3L constructs were prepared using the following primers: the leader peptide forward primer containing KpnI site 5′-AAGAGTACGGACCACTGACCTTCGACCTC TCAG-3′ and reverse primer containing Flag sequence 5′-CTTATCGTCTGTACATCTTGTAAATCGCCAGTGGGCGCCAGTCA-3′; and the mature peptide forward primer containing a Flag sequence 5′-GATTA CAAGGATGAGCAGCGTAAAGCGTCACGCTATCGAATCC-3′ and reverse primer containing XhoI site 5′-GGGCGTGTTAGTACGTTTTTACTTCTGTAATATTATAATC-3′. The PCR products were used as templates for a second round of PCR using the leader peptide forward primer and mature peptide reverse primer to produce full-length cDNA PCR product. The PCR products were inserted into pcDNA3 vector at KpnI and XhoI sites. All constructs were sequenced at the Sequence Center of Brigham and Women’s Hospital. SHP-1 siRNA was purchased from Santa Cruz Biotechnology. The siRNA was transfected into TALL cells with a siRNA transfection protocol (24). Plasmids, short interfering RNA (siRNA) and transfection were performed following standard protocol with modification (28). Ab redirected Ab-dependent cell mediated cytotoxicity and calculation of specific 51Cr release was performed as previously described (25, 26).

RT-PCR

The primers to determine CEACAM1 isoforms were 5′-GCTCTACCA CAAGAAAATGG-3′ (forward) and 5′-CTTATCGTCTGTACATCTTGT AAATCGCCAGTGGGCGCCAGTCA-3′ (reverse). They amplified the L isoform cDNA to produce a 197 bp fragment and the S isoform to produce a 143 bp fragment.

Immunoprecipitation (IP) and Western blotting

IP and Western blotting were performed as previously described (5) by using specific Abs as indicated in results and legends.

Confocal microscopy

TALL cells were incubated with FITC-conjugated rat anti-mouse IgG1. For Lamp1 surface translocation, cells were seeded in a 96-well plate coated with Abs as indicated, incubated in 5% CO2, 37°C incubator for 4 h, and stained with PE-conjugated anti-Lamp1. Stained cells were analyzed on a FACscan platform (BD Biosciences).

Serine esterase release and cytotoxicity assay

Serine esterase assay and calculation of released esterase percentage was performed following standard protocol with modification (28). Ab redirected Ab-dependent cell mediated cytotoxicity and calculation of specific 51Cr release was performed as previously described (25, 26).

Statistics

The student’s t test was used to determine significance. A value of p < 0.05 was considered as significant.

Results

Stimulation of T cells induces expression of L and S CT containing isoforms of CEACAM1

The specific isoforms of CEACAM1 expressed by human T cells is controversial, with some studies showing that human T cells only express L CT isoforms (15). Therefore, to define which isoforms of CEACAM1 are expressed in human T cells, we established primers which amplify a 143 bp fragment from all S isoform cDNAs and a 197 bp fragment from all L isoform cDNAs (data not shown). Using this unique set of primers, we analyzed freshly isolated peripheral blood T (PB T) cells, cloned expanded intestinal intraepithelial lymphocyte (IEL) CD4+ T cells, IEL CD8+ T cell lines, and the CD8+ T cell leukemia TALL 104 (TALL) cell line. The results in Fig. 1A show that all continuously cultured T cells lines expressed high levels of CEACAM1 L isoforms and low levels of CEACAM1 S isoforms. In contrast, unstimulated primary PB T cells expressed negligible levels of both isoforms of CEACAM1. However, after 4 days of culture with IL-2 and PHA, the CEACAM1 mRNA levels in PB T cells reached those of the
clonally expanded IEL T cell lines and TALL cells constantly maintained in IL-2 media with predominant expression of long-CT isoforms of CEACAM1. These results show that increased CEACAM1 transcripts are induced in primary human T cells by activation with IL-2 and PHA, and that the predominant isoforms expressed are those containing αLC T.

To determine whether the CEACAM1 mRNAs that are induced by IL-2 or IL-2 plus PHA result in increased CEACAM1 protein expression, we immunoprecipitated and immunoblotted (IB) CEACAM1 from various T cell lysates using the monoclonal anti-human CEACAM1 Ab (5F4) (26). Fig. 1B shows that CEACAM1 protein could not be detected in resting human PBT cells. However, after 4 days of culture with IL-2 plus PHA, CEACAM1 could be detected at levels that were similar to T cell lines continuously maintained in IL-2. Increasing the culture period to 7 days had no further effect on CEACAM1 mRNA or protein levels of primary human PBT cells (data not shown). Flow cytometry analysis also showed undetectable levels of CEACAM1 on the cell surface of primary human PBT cells (Fig. 1C). However, CEACAM1 surface expression was evident after 4 days of culture in IL-2 and PHA (Fig. 1C). These studies confirm that CEACAM1 is an activation-induced cell surface protein in T cells and, that the predominant forms of CEACAM1 expressed by human T cells are those containing a L CT.

CEACAM1 ITIM phosphorylation and subsequent association with SHP-1 requires Lck and homophilic binding

CEACAM1-L ITIM phosphorylation is required for association with SHP-1 and inhibition of TCR signaling because deletion of critical tyrosine residues within the ITIMs abrogates the inhibitory functions of mouse and human CEACAM1 (7, 14, 29). In addition, phosphorylated, but not nonphosphorylated, CEACAM1 CT containing fusion proteins can associate with SHP-1 in mice (14). We therefore examined tyrosine phosphorylation of endogenous CEACAM1 in T cells cultivated in IL-2. Fig. 2A shows that all activated T cells examined contain tyrosine phosphorylated CEACAM1. Because phosphorylation of CEACAM1 could be due to IL-2 stimulation and/or homophilic ligation of CEACAM1, we pursued the following studies in Jurkat T cells that do not normally express CEACAM1 (8). We transiently transfected Jurkat T cells with WT CEACAM1–3L (3L-WT), CEACAM1–3S (3S-WT), or CEACAM1–3L-FF (3L-FF) in which the two tyrosines in ITIMs were replaced with conservative phenylalanine substitutions as previously described (5). Given that Jurkat T cells do not require
IL-2 and do not spontaneously produce IL-2 in culture, it was interesting to observe that CEACAM1 3L-WT was phosphorylated in Jurkat T cells without stimulation (Fig. 2B). In contrast, neither CEACAM1 3S-WT, nor 3L-FF, which are otherwise identical except for the CT, were not phosphorylated. The latter studies confirm that phosphorylation of CEACAM1 3L-WT occurs on the ITIM tyrosines.

These studies suggested that homophilic interactions are sufficient to induce CEACAM1-L tyrosine phosphorylation. To provide further confirmation, we prepared N-terminal Flag-tagged WT CEACAM1–3L and mutated CEACAM1–3L in which the homophilic binding site was deleted by replacing CEACAM1–3L R43G Q44L as previously described (30). Such mutations of human CEACAM1 abrogate homophilic binding and heterophilic binding of CEACAM1 to the mouse anti-human CEACAM1 Ab 5F4 (30). Although CEACAM1–3LR43G Q44L was able to reach the cell surface at levels similar to that observed with WT CEACAM1–3L (Fig. 2C), there was no evidence for tyrosine phosphorylation of CEACAM1–3LR43G Q44L (Fig. 2D). Thus, tyrosine phosphorylation of CEACAM1 is regulated by homophilic ligation of CEACAM1 in the absence of T cell activation.

In non-T cell types, CEACAM1 has been shown to associate with Src family tyrosine kinases (29). To define which kinase in T cells is responsible for phosphorylating the CEACAM1-L ITIM tyrosines, we performed the following studies. We transiently expressed human CEACAM1–3L in Jurkat T cells. The cells were then treated with a Src tyrosine kinase inhibitor (PP2). As expected, treatment of Jurkat T cells that transiently expressed CEACAM1–3L with PP2 profoundly reduced CEACAM1-L phosphorylation. In contrast, treatment with a vehicle control containing a Src tyrosine kinase-relevant inhibitor (AG1478) specific for the epidermal growth factor receptor, which is not expressed by Jurkat T cells (31) and which has been shown to tyrosine-phosphorylate CEACAM1-L (32), had no effect on CEACAM1-L phosphorylation. To identify the specific tyrosine kinase required for CEACAM1 phosphorylation in T cells, we transiently transfected CEACAM1-3L-WT into WT and Lck-deficient (J.cam1.6) Jurkat T cells. In the absence of Lck, both CEACAM1 phosphorylation and association with SHP-1 were blocked (Fig. 2F). These results indicate that Lck is required for CEACAM1 phosphorylation and SHP-1 association.

To demonstrate an interaction between human CEACAM1 and Lck, we created a GST fusion protein containing the CT of the L isoform CEACAM1 (GST-CT). These studies showed that GST-CT, but not GST, could coimmunoprecipitate Lck from Jurkat T cell lysates (Fig. 2G). Furthermore, when primary PBT cell lysates were immunoprecipitated with an anti-CEACAM1 Ab and the immune-complexes analyzed by immunoblot with an anti-Lck Ab, we observed an association between endogenous CEACAM1 and Lck (Fig. 2H). Similar results were obtained using clonally expanded IEL and TALL cells (data not shown). Interestingly, the association between CEACAM1 and Lck was observed to decrease shortly after TCR engagement with anti-CD3 (Fig. 2H), suggesting that CEACAM1 association with Lck was mainly due to an association with nonphosphorylated CEACAM1 (see Fig. 2G) or that Lck was displaced by an association with SHP-1 (see following results).

**CEACAM1 recruits SHP-1 to deactivate ZAP-70**

To define the immediate elements that are influenced by the interaction of the ITIMs of CEACAM1 and SHP-1, we evaluated the effect of CEACAM1 ligation on CD3-ζ and ZAP-70 tyrosine phosphorylation. TALL cells were treated with anti-CD3-ε with or without an anti-CEACAM1 Ab that binds to the homophilic binding site (5, 26, 30, 33) followed by crosslinking with a F(ab′)2 goat anti-mouse IgG for 2 min. Phosphorylation of CD3-ζ and ZAP-70 was then assessed by IB with corresponding phosphotyrosine specific Abs. The results in Fig. 3A show that coligation of CEACAM1 caused a profound decrease in TCR stimulation-induced CD3-ζ and ZAP-70 phosphorylation. However, the total CD3-ζ and ZAP-70 were not changed (shown herein is only ZAP-70). Similar results were obtained with clonally expanded IEL cells (data not shown).

To interrogate the mechanism by which CEACAM1 recruits SHP-1 to TCR signalosome, we performed coimmunoprecipitation assays and confocal microscopy. As shown in Fig. 3B, Abs against CEACAM1, CD3-ε-chain, and the TCR-β-chain coprecipitated CEACAM1 from TALL cell lysates, showing that CEACAM1 interacts with the endogenous TCR/CD3 complex. Interestingly, an Ab specific for the TCR-α-chain did not coimmunoprecipitate CEACAM1, suggesting that CEACAM1 is mainly associated with the TCR-β but not TCR-α chain or that the TCR-α Ab used induced dissociation of CEACAM1. Fig. 3C shows that CEACAM1 and the TCR/CD3 localize on cell surface and exhibit significant colocalization. Upon stimulation of the TCR/CD3 complex, the colocalization was markedly increased especially intracellularly, indicating stimulation of the TCR/CD3 complex caused significant cointernalization with CEACAM1. When T cells were stimulated with an anti-CEACAM1 Ab, we also observed an intensive colocalization of CEACAM1 and the TCR/CD3 complex intracellularly. These studies indicate a physiological association of CEACAM1 and TCR/CD3 complex.

To determine whether CEACAM1 recruits SHP-1 to the TCR signalosome upon TCR stimulation, Jurkat T cells either stably expressing CEACAM1-4L or CEACAM1–4S were stimulated with FITC-conjugated anti-CD3 for 5 min, fixed, and stained for CEACAM1 and SHP-1. The results shown in Fig. 3D indicate that under these conditions the TCR/CD3 complex, CEACAM1, and SHP-1 colocalize in punctate structures at the plasma membrane in CEACAM1–4L transfected cells. In contrast, in CEACAM1–4S transfected cells colocalization was observed only between the TCR/CD3 complex and CEACAM1 as revealed by confocal microscopy. In addition, Jurkat T cells stably expressing CEACAM1–4L, but not CEACAM1–4S, was observed to associate with SHP-1 within 2 min of anti-CD3 stimulation (Fig. 3E). Taken together with the microscopy studies (Fig. 3D), these studies indicate that the ITIMs of CEACAM1 recruit SHP-1 that in turn mobilizes SHP-1 to the TCR signalosome.

The kinetics of CEACAM1 association with SHP-1 (Fig. 3E) was reciprocal to that observed for Lck association (Fig. 2H) suggesting that CEACAM1 interacts sequentially with Lck and SHP-1 and may account for the dephosphorylation of ZAP-70. Thus, to demonstrate that the SHP-1, which is associated with CEACAM1, can dephosphorylate elements within the TCR signalosome, we incubated T cell lysates with anti-SHP-1 or isotype control IgG coupled to protein-G Sepharose beads twice to deplete SHP-1 and then isolated CEACAM1 by IP with 5F4. The CEACAM1 isolated in this manner that was depleted or not depleted of coassociated SHP-1 was then tested for its ability to dephosphorylate ZAP-70. As expected, when SHP-1 was depleted from lysates using a SHP-1 specific Ab (Fig. 3F), but not an IgG control, CEACAM1 lost the ability to dephosphorylate active ZAP-70. These studies indicate that a CEACAM1/SHP-1
complex in the TCR signalosome is able to dephosphorylate ZAP-70 and/or CD3-ζ/H9256.

CEACAM1 engagement prevents activation of ZAP-70-related signaling pathways

Based on the results presented above, we predicted that coengagement of CEACAM1 would inhibit activation of other signaling elements downstream of ZAP-70 that are induced by TCR/CD3 complex stimulation. To confirm this prediction, TALL cells were treated with anti-CD3 with or without the anti-CEACAM1 mAb 5F4 or an isotype control IgG followed by crosslinking with F(ab’2)2 goat anti-mouse IgG for 2 min. Activation of LAT, PLCγ1, and ERK was evaluated by immunoblot of whole cell lysates with the corresponding anti-phospho-specific Abs. SLP-76 activation was assessed by IP of SLP-76 followed by immunoblot with an anti-p-Tyr Ab. Coengagement of the TCR/CD3 complex and CEACAM1 decreased the phosphorylation and thus the activation of LAT, SLP-76, PLCγ1, and ERK compared with that induced by TCR/CD3 stimulation alone (Fig. 4).
CEACAM1 engagement inhibits TCR-mediated cytotoxicity by blocking granule exocytosis

Previous studies have shown that CEACAM1 engagement of stimulated CD8+ IELs (26) and tumor infiltrating CD8+ T cells (9) inhibits cytolytic function. ZAP-70 signaling is involved in TCR cytolytic function (34, 35). We therefore confirmed that CEACAM1 engagement inhibited anti-CD3 redirected target cell lysis of P815 cells (Fig. 5, A–C). As seen in Fig. 5D, anti-CD3 ligation inhibited anti-CD3-stimulated granule exocytosis. To confirm this, granule movement from the cytoplasm to the surface membrane was assessed by Lamp1 staining of the cell surface after CD3 stimulation in the presence or absence of increasing concentrations of the CEACAM1-specific mAb 5F4 or control mouse IgG1. As shown in Fig. 5E, the 5F4 mAb, but not an isotype control, caused a significant reduction of Lamp1 accumulation on the surface. These studies show that coligation of CEACAM1 with the TCR/CD3 complex results in inhibition of granule exocytosis and consequently diminished cytotoxicity, functions that are downstream of ZAP-70.

Silencing of SHP-1 and blockade of the CEACAM1 N-domain reverses CEACAM1-mediated inhibition

To determine whether CEACAM1-mediated inhibition of TCR signaling is physiologically affected by SHP-1-mediated dephosphorylation of ZAP-70, we silenced SHP-1 expression in T cells by transfection of TALL cells with SHP-1-specific siRNA. As shown in Fig. 6A, treatment of TALL cells with SHP-1 siRNA resulted in decreased SHP-1 protein expression in comparison to that observed in cells treated with a mock siRNA. In comparison, treatment of TALL cells with SHP-1 siRNA did not affect expression of ZAP-70 (Fig. 6A). We next evaluated the effects of SHP-1 silencing on ZAP-70 phosphorylation induced by ligation with anti-CD3 or anti-CD3 in the presence of CEACAM1 ligation. Whereas ZAP-70 phosphorylation induced by anti-CD3 ligation was inhibited in control cells treated with anti-CEACAM1 in the presence of mock siRNA, CEACAM1-mediated inhibition of anti-CD3-induced ZAP-70 phosphorylation was reversed in cells treated with SHP-1 siRNA (Fig. 6A). We next investigated the effects of SHP-1 silencing on Lamp1 surface accumulation upon TCR/CD3 complex engagement in the presence or absence of CEACAM1 ligation. As shown in Fig. 6B, redistribution of Lamp1 to the cell surface induced by anti-CD3 was inhibited by coengagement of CEACAM1 with the 5F4 mAb. This inhibition of Lamp1 redistribution to the cell surface by coligation of CD3 and CEACAM1 was not affected by mock siRNA. In comparison, ligation of CEACAM1 by the 5F4 was unable to effect suppression.
of Lamp1 expression on the cell surface when SHP-1 expression was silenced by treatment with specific siRNA (Fig. 6B). These results are consistent with previous studies showing that SHP-1 siRNA can reverse suppression of TCR-induced NFAT activation by CEACAM1 (5), and that CEACAM1–4L overexpression in normal T cells, but not in SHP-1 deficient T cells, can inhibit T cell transfer colitis (7).

Finally, to confirm that homophilic ligation is involved in CEACAM1-mediated inhibition and to identify an antagonist that can specifically block CEACAM1 homophilic binding, we generated Fab fragments (data not shown) of the human CEACAM1-specific mAb, 5F4, that binds to the homophilic binding motif of CEACAM1 (30, 33). Fig. 6C confirms previously published work of Markel and colleagues (30) that the 5F4 Ab interacts with the homophilic binding site of the CEACAM1 N-domain as staining of T cells expressing the CEACAM1–3L Q44L mutant is lost in comparison to staining of the WT CEACAM1–3L isoform. In comparison, the mouse anti-human CEACAM1 mAb 34B1 (26), which binds outside of the homophilic binding site (33), stains both the WT and mutant CEACAM1–3L isoforms (Fig. 6C). The IgG control Ab bound neither WT nor mutated CEACAM1 (data not shown). Fab of the 5F4 mAb were therefore tested for their ability to regulate the T cell function. Anti-CD3 treatment of TALL cells induced an increase in Lamp1 accumulation on cell surface as seen in Fig. 6D (solid histograms; middle and right panels) relative to that observed in untreated cells (solid histogram; left panel). Pretreatment of TALL cells with the Fab of 5F4 significantly increased the accumulation of Lamp1 on the cell surface beyond that induced by anti-CD3 stimulation alone (Fig. 6D; open histograms). Importantly, the Fab alone did not induce Lamp1 accumulation on the cell surface in the absence of TCR stimulation (Fig. 6D, left panel). These studies confirm CEACAM1 as a coinhibitory receptor and indicate that CEACAM1-mediated inhibition occurs by homophilic engagement.

Discussion

The inhibitory function of CEACAM1 is dependent on the ITIM domains within the CT of CEACAM1 and SHP-1 because deletion of either abrogates CEACAM1-mediated inhibition. The tyrosine phosphorylation of the ITIMs of CEACAM1 is a prerequisite for CEACAM1 association with SHP-1 in mouse T cells (14) and SHP-1 as well as SHP-2 in epithelia cells (36, 37). However, there exists three fundamental unanswered questions by which CEACAM1 functions in T cells that are what initiates CEACAM1 ITIM phosphorylation, which tyrosine kinase phosphorylates CEACAM1 ITIMs, and how does SHP-1 association with CEACAM1 inhibits TCR/CD3 complex signaling. We now demonstrate that the tyrosine phosphorylation of CEACAM1 L isoforms is initiated by the ability of CEACAM1 to exhibit homophilic binding through its N-domain. Physiologically, this is predicted to occur at high T cell densities with other CEACAM1 bearing cells. In addition, we show that Lck is the tyrosine kinase that is required for phosphorylation of the CEACAM1 ITIMs. In Lck-deficient T cells, CEACAM1 cannot be phosphorylated at tyrosine residues and consequently CEACAM1 lacks the ability to associate with SHP-1. This is consistent with previous observations that the tyrosines within the ITIMs of CEACAM1 can be phosphorylated by c-Src kinase in epithelial cells (29, 32), Btk kinase in B cells (24), Lyn in neutrophils (38, 39), and insulin receptor tyrosine kinase as well as epidermal growth factor receptor tyrosine kinase (40, 41). Specific dependence on Lck for CEACAM1 tyrosine phosphorylation in T cells is consistent with a similar role for Lck in mediating tyrosine phosphorylation of FcyRIIb in NK cells (42). We further show that Lck likely directly phosphorylates the CEACAM1 ITIM tyrosines because endogenous CEACAM1 constitutively associates with Lck. In addition, a GST fusion protein containing the CEACAM1 CT can associate with Lck. However, it is still possible that tyrosine phosphorylation of CEACAM1 is mediated by another tyrosine kinase that requires Lck in T cells. Taken together, these studies suggest that the cell surface of CEACAM1 may induce association of itself with Lck, which is further enhanced by TCR/CD3 complex activation.

The interaction between CEACAM1 ITIMs and SHP-1 suppresses multiple different functions initiated by TCR/CD3 complex signaling including proliferation, cytokine secretion, and cytotoxicity (5, 8–10, 26). However, the final common pathway by which this occurs has been unknown. In this study, we show that coligation of CEACAM1 decreases phosphorylation of CD3-ζ and ZAP-70 induced by stimulation of the TCR/CD3 complex. CD3-ζ is a direct adaptor of the TCR and recruits ZAP-70 to immune synapses upon TCR stimulation. In the immune synapse, ZAP-70 is activated (43) and subsequently functions as a central organizer.
of several downstream signaling events (44, 45). The current study shows that CD3-ζ and/or ZAP-70 are the proximal elements that are influenced by the interaction of CEACAM1 and SHP-1. Consistent with this, we now show that CEACAM1 inhibits cytotoxicity by reducing degranulation; a process that is downstream of ZAP-70 (35). Although SHP-1 has been shown to inhibit TCR signaling through dephosphorylation of CD3-ζ and ZAP-70 (46, 47), SHP-1 is normally excluded from membrane lipid rafts (48, 49) where the TCR/CD3 complex localizes (50). Therefore, the mechanism by which SHP-1 accesses the TCR signalosome has been an open question. SHP-1 has been shown to associate with co-inhibitory receptors, including killer inhibitory receptors (42), CTLA-4 (4, 51), and PD-1 (47). Nevertheless, it is not known whether these co-inhibitory receptors can recruit SHP-1 to the TCR signalosome. Our study demonstrates that CEACAM1, which is able to shuttle between lipid rafts and nonlipid raft membranes, can associate with the TCR/CD3 complex. Furthermore, this association is increased by TCR/CD3 complex engagement and is relevant to TCR/CD3 complex function as we observed colocalization and cointernalization of the TCR/CD3 complex. These studies thus suggest that CEACAM1 facilitates entry of SHP-1 into the vicinity of the TCR/CD3 complex signalosome that is rich in lipid rafts (50) and provide evidence to explain previous observations that stimulation of T cells induces SHP-1 translocation to lipid rafts where it dephosphorylates ZAP-70 and/or CD3-ζ (46).

In addition, previous studies have demonstrated that both the anti-human CEACAM1 monoclonal body 5F4 that recognizes the homophilic binding site within the C-C' loop of the human CEACAM1 N-domain and the 34B1 mAb that recognizes the N-domain outside of the C-C' loop can induce CEACAM1 to transduce inhibitory signals in human T and/or NK cells (5, 26, 30, 33). This indicates that CEACAM1 may be able to bind multiple ligands that can trigger inhibitory signaling, which is consistent with CEACAM1-mediated inhibition induced by the murine hepatitis virus spike glycoprotein (6). CEACAM1 containing mutations in the Arg43 and Gln45 residues (R43GQ45L) loses the ability to bind to CEACAM1 itself as well as CEACAM5 and the 5F4, but not the 34B1, mAb and loses the ability to inhibit NK cell-mediated cytotoxicity (30). These studies indicate, in particular, that the 5F4 mAb binds within the homophilic binding site. Moreover, in line with these previous studies, masking the homophilic binding site of CEACAM1 with a Fab of the 5F4 mAb enhances the cytolytic function of T cells (Fig. 6D). Taken together, these studies now show that the 5F4 mAb binds within the homophilic binding site and is agonistic.

In summary, we show that expression of LCT containing isoforms of CEACAM1 in T cells is induced by activation and, furthermore, the activity of CEACAM1 is dependent upon homophilic binding. This ability to interact homophilically allows for association of CEACAM1 with and phosphorylation by the Src kinase, Lck, which is sequentially replaced by an association between CEACAM1 and SHP-1 which is brought into the vicinity of the TCR/CD3 complex where it dephosphorylates the most proximal signaling elements and associated adaptors of the TCR/CD3 complex, namely CD3-ζ and ZAP-70. These studies thus explain how CEACAM1 expression on T cells has such a profound impact on diverse cellular functions (6, 8, 9, 26, 52) making CEACAM1 of significant importance to a variety of immune responses as potentially diverse as inflammation, autoimmunity, and tumor immunity.

Acknowledgments

We owe thanks to Dr. John E. Shively for kindly providing the human CEACAM1−4L and -4S Jurkat T cell lines and to Dr. Bana Jabri for generously providing clonally expanded human CD4+ and CD8+ T cell clones. We thank Dr. Lewis Lanier for useful discussions and volunteer student Yiling Chen for assistance in completion of the GST-CT fusion protein. We also appreciate Dr. Nicolas Kupferwasser for help in preparing the figures.

Disclosures

The authors have no financial conflict of interest.

References


embrionic antigen-related 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor. J. Immunol. 172: 3544–3552.


placement of the short cytoplasmic domain isoform by glycosylphosphatidyli-


